Corvus Pharmaceuticals
CRVS
49 hedge funds and large institutions have $62.8M invested in Corvus Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 8 closing their positions.
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
29% more funds holding
Funds holding: 38 → 49 (+11)
8% more capital invested
Capital invested by funds: $58.1M → $62.8M (+$4.74M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.9% less ownership
Funds ownership: 58.13% → 53.24% (-4.9%)
80% less call options, than puts
Call options by funds: $93K | Put options by funds: $462K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.64M |
| 2 |
O
OrbiMed
New York
|
+$4.64M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
| 4 |
Two Sigma Investments
New York
|
+$1.26M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.02M |
| 2 |
Renaissance Technologies
New York
|
-$483K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$259K |
| 4 |
Goldman Sachs
New York
|
-$184K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$151K |
CRVS Hedge Fund Activity: Q1 2021 in Review
49 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2021, worth a combined $62.8M — up 8.2% from $58.1M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CRVS positions and 8 closed out — a net gain of 11 holders — while 16 added to existing stakes and 8 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.64M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $3.02M sold.
- 49 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2021, up from 38 in Q4 2020.
- Funds reported $62.8M of Corvus Pharmaceuticals stock for Q1 2021, up 8.2% quarter-over-quarter.
- 19 funds opened new Corvus Pharmaceuticals positions in Q1 2021 and 8 closed out, a net change of +11 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2021 was BVF Inc, an estimated $4.64M added.
- The largest Corvus Pharmaceuticals seller in Q1 2021 was Novo Holdings A/S, an estimated $3.02M sold.
Based on aggregated 13F filings for Q1 2021.